tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Cell-in-a-Box'

PharmaCyte Biotech Equity Research by Stonegate Capital Partners

PharmaCyte Biotech Equity Research by Stonegate Capital Partners

On May 28, 2015, Stonegate Capital Partners released an extensive Equity Research Report on PharmaCyte Biotech, Inc.  The firm’s reports are issued to targeted funds, and institutional investors also have access to Stonegate’s research from a variety of services including Bloomberg, Thomson Reuters, Zach’s, Capital IQ, The Markets, Morningstar and FactSet among others. Stonegate has the ability to actively track the institutional investors who access their research.

Click to View Stonegate Capital Partners Equity Research on PharmaCyte ...

Read More →
0

PharmaCyte Biotech Creates Faster Path to the Clinic For Company’s Diabetes Treatment

PharmaCyte Biotech Creates Faster Path to the Clinic For Company’s Diabetes Treatment

Written by Ι Stock Market Media — May 20, 2015

PharmaCyte Biotech (OTCQB: PMCB) has managed to do something that is rarely done in science – bring together an international group of leading experts to work on one project. The project that is drawing their interest is PharmaCyte Biotech’s diabetes treatment and getting it into the hands of insulin-dependent patients around the world. These experts have become known collectively as the “International Diabetes Consortium,” and if PharmaCyte is to be successful, it will ...

Read More →
0

Nuvilex Announces Name Change to PharmaCyte Biotech

Nuvilex Announces Name Change to PharmaCyte Biotech

Company’s Shares Will Trade Under New Ticker Symbol PHCB

SILVER SPRING, MD., Jan. 7, 2015 — Nuvilex, Inc. (NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change ...

Read More →
0

FDA Grants Orphan Drug Designation to Nuvilex, Inc. for Pancreatic Cancer Treatment

SILVER SPRING, Md., Dec. 22, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex’s pancreatic cancer treatment combines Nuvilex’s patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box(R), with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are ...

Read More →
0

Nuvilex Announces Preliminary Data from Preclinical Study of Effects of its Pancreatic Cancer Treatment on Ascites Fluid Formation

SILVER SPRING, MD, November 19, 2014 – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of Nuvilex’s pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. This study, performed by Nuvilex contractor, Translational Drug Development (TD2), employed immunosuppressed mice implanted with disseminated human ovarian cancer cells into the peritoneal cavity.

Preliminary ...

Read More →
0

Nuvilex, Inc. Engaged in “Cutting Edge” Cannabis Preclinical Studies Using Model Compounds with Cell-in-a-Box

Written by Ι Stock Market Media Group Staff — October 29, 2014

New York, NY – Nuvilex, Inc. (OTCQB: NVLX) isn’t letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its research.  The company is currently engaged in preclinical studies at the University of Northern Colorado (UNC) targeting Cannabis-based cancer treatments using Nuvilex’s Cell-in-a-Box® cellulose-based live cell encapsulation technology. 

While waiting for a Schedule 1 license from the DEA in order to conduct research using marijuana, Dr. ...

Read More →
0
Page 3 of 9 12345...»
ContactUs.com